^
Association details:
| Biomarker: | NF1 mutation |
|---|---|
| Cancer: | Neurofibrosarcoma |
| Drug Class: | MEK inhibitor + c-MET inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors
Excerpt:
...a combination of MEK and MET inhibition demonstrated activity in models of MPNST and may therefore be effective in patients with MPNST harboring genetic alterations in NF1….study demonstrates that MEKi plus MET inhibitor may delay or prevent a novel mechanism of acquired MEKi resistance, with clinical implications for MPNST patients harboring NF1 alterations.
DOI:
10.1158/0008-5472.CAN-20-1992
